Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KSP-1007 +/- Meropenem in Healthy Subjects
NCT05226923Phase 1Completed
- Sponsor
- Sumitovant Biopharma
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KSP-1007 in bacterial infection (6 arms), sponsored by Sumitovant Biopharma. Primary endpoint: Incidence of adverse events assessed by subject. Started Jan 2022; status: completed.
02
Drugs
KSP-1007
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05226923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226923.